Contineum Therapeutics, Inc. (CTNM)
Last updated: 2026-10-20 21:51:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Contineum Therapeutics, Inc. (CTNM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.48, with a market capitalization of $266.36M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.73 to $17.79. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$266.36M | |
$7.21 | |
$22.00 | |
$3.35 | |
$7.44 | |
2.09M | |
767.23K | |
-- | |
$17.79 | |
$6.73 | |
-- | |
-- |
Contineum Therapeutics, Inc. (CTNM) After-Hours Stock Price
Contineum Therapeutics, Inc. (CTNM) is trading at $8.48 in after-hours trading as of 2026-10-20 21:34:00, up 13.98% ($1.04) from the regular-session close of $7.44.
After-hours trading shows how investors are pricing CTNM after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Contineum Therapeutics, Inc. (CTNM) 7-Day Stock Price Change
Over the past seven days, Contineum Therapeutics, Inc. (CTNM) moved from $13.38 to $8.48, representing a decline of 36.64% ($4.90).
The stock traded between $6.73 and $13.86 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.42 million shares, up versus the previous seven-day period, indicating higher trading activity.
CTNM 52-Week Price Position
Position in Range: 15.8%
CTNM is currently trading at $8.48, placing it 15.8% of the way from its 52-week low of $6.73 to its 52-week high of $17.79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Contineum Therapeutics, Inc. (CTNM)?
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Contineum Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 51 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Contineum Therapeutics, Inc. (CTNM) Stock on MEXC
Eligible investors can buy real shares of Contineum Therapeutics, Inc. (CTNM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Contineum Therapeutics, Inc. (CTNM) stock price today?
2.Is CTNM stock going up or down today?
3.What is CTNM pre-market price?
4.What is CTNM after-hours price?
5.Is CTNM stock trading now?
6.Where does CTNM sit relative to its 52-week high and low?
7.What sector is Contineum Therapeutics, Inc. in?
8.What is Contineum Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is CTNM valued in terms of P/E ratio and EPS?
10.Does Contineum Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
CTNM Stock Calculator
Estimate the value between CTNM shares and USD.
CTNM Shares to USD
1.00 CTNM shares = 8.478 USD
Calculations are estimates based on the latest available price and are for reference only.


